Implication of Apoptosis for the Pathogenesis of Trypanosoma cruzi Infection

Débora Decote-Ricardo1, Marise P. Nunes2, Alexandre Morrot3* and Celio G. Freire-de-Lima4*

1 Instituto de Veterinária, Universidade Federal Rural do Rio de Janeiro, Seropédica, Brazil, 2 Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 3 Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 4 Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Apoptosis is induced during the course of immune response to different infectious agents, and the ultimate fate is the recognition and uptake of apoptotic bodies by neighboring cells or by professional phagocytes. Apoptotic cells expose specific ligands to a set of conserved receptors expressed on macrophage cellular surface, which are the main cells involved in the clearance of the dying cells. These scavenger receptors, besides triggering the production of anti-inflammatory factors, also block the production of inflammatory mediators by phagocytes. Experimental infection of mice with the parasite Trypanosoma cruzi shows many pathological changes that parallels the evolution of human infection. Leukocytes undergoing intense apoptotic death are observed during the immune response to T. cruzi in the mouse model of the disease. T. cruzi replicate intensely and secrete molecules with immunomodulatory activities that interfere with T cell-mediated immune responses and secretion of pro-inflammatory cytokine secretion. This mechanism of immune evasion allows the infection to be established in the vertebrate host. Under inflammatory conditions, efferocytosis of apoptotic bodies generates an immune-regulatory phenotype in phagocytes, which is conducive to intracellular pathogen replication. However, the relevance of cellular apoptosis in the pathology of Chagas’ disease requires further studies. Here, we review the evidence of leukocyte apoptosis in T. cruzi infection and its immunomodulatory mechanism for disease progression.

Keywords: Trypanosoma cruzi, apoptosis, immunomodulation, infection, macrophages

INTRODUCTION

Chagas disease or American trypanosomiasis was discovered by Carlos Chagas in the early twentieth century. The disease is caused by the protozoan parasite Trypanosoma cruzi. It is estimated that 18–20 million people in Latin America are infected with T. cruzi, and approximately 100 million people are living in areas at risk of infection (1). T. cruzi is an obligate intracellular parasite that infects a variety of the mammalian host cells but shows preference for cells of the macrophage and muscle lineage.
The biological cycle in man has two evolutionary forms (1) trypomastigotes, the flagellate form of the parasite that invades cells, where they differentiate into (2) amastigotes that have no free flagellum and replicate inside almost all nucleated cells of the vertebrate host (2). Soon after infection, trypomastigotes have the ability to escape the parasitophorous vacuole and differentiate into amastigotes in the host cell cytoplasm. After several rounds of binary divisions inside the infected cells, amastigotes differentiate to trypomastigotes forms, lyse the infected cells, and reinvade adjacent cells (3, 4).

An important successful factor that allows T. cruzi to survive in the vertebrate host is the evasion of the cellular immune response (5–7). Many studies in this area describe the existence of different strategies developed by the parasite to modulate the immune response of the vertebrate host in its favor (4, 8–12).

One of the most efficient mechanisms that T. cruzi parasites use to establish a persistent infection is the induction of T and B cell apoptosis, and such process has immunomodulatory effects on the host immune response (8, 13).

**APOPTOSIS AS A HALLMARK OF T. cruzi INFECTION**

Apoptosis is crucial for normal tissue homeostasis and for modulation of immune response. During parasitic infections, apoptosis or programmed cell death can be triggered by antigens, factors secreted and/or released by pathogens, by chronic infection, and by intense cellular activation (14–16). Recent evidences have shown that in order to survive in their hosts, intracellular protozoan parasites have to limit the defense mechanisms and are taking advantage of cell death to facilitate parasitic spreading. It was described that T. cruzi infection triggers activation-induced cell death (AICD) of CD4+ T lymphocytes during the acute phase of infection (8, 17). The AICD occurs after stimulation with anti-TCR and anti-CD3 agonist antibodies in vitro. When cultured in the presence of anti-Fas agonist antibody, CD4+ T cells from infected mice, but not from normal mice, undergo apoptosis (17, 18).

The interaction between the Fas molecule (CD95) and its ligand, the Fas ligand (FasL) molecule (CD95L) induces death by apoptosis (19). The involvement of Fas/FasL molecules was confirmed during the acute phase of T. cruzi experimentally infected mice. It was found that there is an increased expression and function of the Fas/FasL in CD4+ T cells, and cells from FasL-deficient mice (gld mice) do not undergo AICD during T. cruzi infection (20). It has been suggested that AICD could have a deleterious role in T. cruzi infection, causing early elimination of effector T cells and supporting parasite escape (13). In agreement with these results, Rodrigues et al. (21) observed high levels of FasL in the serum of T. cruzi chronically infected patients (21). In addition, studies by Guillermo et al. (22) and Vasconcelos et al. (23) have revealed more information about the kinetics of Fas/FasL expression and T lymphocytes apoptosis during T. cruzi experimental infection (22). Splenic CD4+ and CD8+ T cells showed an upregulation in CD95/CD95L expression in a time-dependent manner during T. cruzi acute infection, which was associated with activation-induced cell death (AICD). In vivo injection of anti-FasL, but not anti-TNF-alpha or anti-TRAIL antibodies, blocked activation-induced cell death of CD8+ T cells, improved type 1 immune responses, and reduced the infection severity as estimated by parasitemia (22, 23). Recently, Chaves et al. (24) demonstrated that T cell apoptosis was related to decreased cell proliferative and modulation of genes associated with apoptosis and caspase family receptors in chagasic patients with heart problems. Thus, the authors concluded that the T cell death was interfering with the clinical manifestations of the disease (24).

Infection caused by T. cruzi results in polyclonal lymphocyte activation (24–27), which, by itself, triggers T cell apoptosis (28, 29). T. cruzi released molecules such as trans-sialidase, an enzyme that catalyzes the transfer of exogenous sialic acid residues from the host acceptor molecules on the T. cruzi surface, induces a strong cell death by apoptosis and resulted in increasing parasite infectivity (30–32).

The T. cruzi surface expresses an unusual family of glycoinositolphospholipid (GIPL) molecules that are present in all T. cruzi evolutionary forms (33). Studies from our group have shown that in the presence of the cytokine IFN-γ, the ceramide portion of the GIPL induced intense macrophage apoptosis, independent of nitric oxide production. This effect was not observed when macrophages were treated with intact T. cruzi GIPL or with the GIPL-derived glycan chain. In T. cruzi-infected macrophages, apoptosis also increased the release of infective trypomastigotes and spheromastigotes (34). The pro-apoptotic action of ceramide had been described in previous studies, in which permeable ceramides were shown to promote a strong cytotoxic effect of this molecule (35, 36). Recently, the α-galactosylceramide molecule derived from T. cruzi induced NK T cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation (37).

Clearance of apoptotic cells involves the recognition of the dying cell by the phagocytes, internalization, the immunological consequences to host–parasite interaction, and pathogenesis of disease (38). In recent years, the term “efferocytosis” has been introduced to specifically refer to the engulfment or phagocytosis of apoptotic cells (39–42). Macrophages undergo specific molecular and functional changes upon encounter, interaction with, and uptake of apoptotic cells (efferocytosis) that control both phagocytosis and immune signaling (42).

In vitro studies showed that engulfment of apoptotic CD4+ T lymphocytes from infected mice by T. cruzi experimentally infected macrophages exacerbate parasite replication. When apoptosis of CD4+ T cells from infected mice was blocked with anti-Fasl. mAb, parasite growth was also blocked. Prevention of parasite growth was observed in a transwell coculture system, where CD4+ T cells were cultured and separated from infected macrophages, showing that the contact and phagocytosis of apoptotic cells ensures parasite replication. This finding was also associated with decreased IFN-γ production, suggesting that AICD was occurring on Th1 CD4+ cell population (18). Apoptotic cells trigger production of anti-inflammatory cytokines such as IL-10 and TGF-β by the phagocytes (41, 43–47). The process of
apoptotic cells uptake by *T. cruzi*-infected macrophages is associated with the release of TGF-β IL-10 and prostaglandin PGE₂ (8, 9, 12). Together, these mediators would deactivate macrophages and favor the growth of *T. cruzi* amastigotes and other intracellular parasites (8, 18, 48).

Phagocytic cells express on the cell surface a group of receptors that actively participate in the recognition and capture of apoptotic bodies, the vast majority of these receptors have affinity to phosphatidylycerine (PtdSer) expressed by apoptotic cells (49). The integrin αVβ3 is one of these receptors, which recognizes PtdSer through molecules that act as bridges, such as lactadherin, glycoprotein produced by phagocytes, and the fat globule of opsonin-factor-8 EGF (MFG-E8) (50). In addition, the αβ3 integrin express on phagocytes can bind to thrombospondin, helping the recognition of PS on the surface of apoptotic cells (51). Other apoptotic cell recognition receptors, such as the family of receptor tyrosine kinases Tyro3, Axl, and MerTK (TAM), also need to bind to bridge molecule to interact with PtdSer on the surface of apoptotic cells (52–54).

Because *T. cruzi* is an intracellular pathogen that cannot produce putrescine, and is a auxotrophic parasite for polyamines, because of its incapacity to produce putrescine due to the lack of both, ornithine decarboxylase (ODC) and arginine. *T. cruzi* needs to capture exogenous putrescine for the proliferation of amastigote forms within the cells (55, 56). Besides the fact that binding of apoptotic lymphocytes to αβ, expressed by macrophages results in secretion of PGE₂ and TGF-β, the engulfment of apoptotic cells is also followed by induction of ODC and synthesis of putrescine: this functions as a growth factor for intracellular forms of *T. cruzi* (8, 9). In addition, this deleterious effect of apoptotic cells is eradicated by inhibitors of prostaglandin synthesis (NSAIDs drugs) and neutralizing antibodies for TGF-β (11, 12). Injection of apoptotic cells increases parasitemia in vivo, and treatment with the cyclooxygenase inhibitors aspirin or indomethacin reduces parasitemia (8).

The use of NSAIDs in *T. cruzi* experimental infection has been used by different groups. However, it is important to emphasize that the use of cyclooxygenase blockers in experimental infection may lead to conflicting results, depending on the experimental model (8, 11, 57, 58). Recently, it was described that aspirin in low doses decreased mortality, parasitemia, and heart damage in *T. cruzi*-infected mice, and they suggested that the protective effect was established to the generation of anti-inflammatory mediator 15-epi-LXA4 (59). However, when aspirin was given in high doses, this protective effect disappeared (59). Also, it has been characterized that the use of COX inhibitors inhibits *T. cruzi* infection of murine cardiac cells (60). The results presented by Michelin and collaborators suggest that the prostaglandins produced mainly by the activation of the COX-2 enzyme favor the immunosuppression of the acute phase of infection (61). These data reinforce our hypothesis that NSAIDs may somehow favor the immune response of the vertebrate host (8, 11).

The contribution of apoptotic T cell pathways in the outcome of *T. cruzi* infection in vivo was addressed by injection of caspase 8 inhibitor or by the use of caspase 8-deficient mice. However, blockade of the initiator caspase 8 in vivo was unable to inhibit apoptosis, and mice that have received treatment demonstrated a profound CD8⁺ T cell depletion. Furthermore, caspase 8-deficient mice upregulated Th2 cytokine responses and increased susceptibility to *T. cruzi* infection (62). Therapy with zvETG (caspase 8 inhibitor), initiated 4 days after infection, resulted in inhibition of T cell expansion and increased parasitemia (62). In contrast, administration of zVAD, a pan caspase inhibitor (or anti-FasL antibody) initiated at day 7 after *T. cruzi* infection was shown to reduce T cell death, promotes type 1 immune response and reduced parasitemia. Spleen cells produced more IFN-γ when stimulated with parasite antigens, while peritoneal macrophages showed a reduced parasite load (63). The number of inflammatory cells in the hearts of acutely infected mice injected with zVAD was not affected (63). Treatment with anti-FasL mAb starting at 11 days after infection, but not anti-TNF or anti-TRAIL antibodies, protect CD8 T cells from AICD, improved cytokine production by CD4 T cells, activate CD8 T cells, upregulate Fas expression by CD8 T cells earlier than CD4 T cells, and decreased parasitemia (22). Mice vaccinated with an adenoviral vector expressing two *T. cruzi*-dominant epitopes improved CD8 T cell functionality and decreased parasitemia after parasite challenge, a phenotype attributed to the lack of CD95 expression in parasite-specific CD8 T cells (23). Recently, Cabral-Piccin and collaborators demonstrated that treatment of *T. cruzi*-infected mice with anti-FasL prevents CD8⁺ T lymphocytes apoptosis, upregulates type 1 responses to parasite antigens, and reduces macrophages infection when cocultured with CD8 T cells (64). Further analysis showed that injection of anti-FasL mAb resulted in a polarized M1 macrophage phenotype, both in vitro and in vivo. The authors suggested that rescuing CD8 T cells from death with anti-FasL treatment prevents the negative effects of efferocytosis on macrophage activation.

**CONCLUDING REMARKS**

The role of T cells-mediated immune response in controlling intracellular protozoan parasite infection is well established. In the acute phase of infection, *T. cruzi* proliferates within the cells of the vertebrate host, besides producing and secreting molecules with immunomodulatory activities that obstruct the immune response mediated by T lymphocytes. The final result of this important modulatory mechanism is the propagation of *T. cruzi* to different organs of the vertebrate host (13). It is also clear that T cell apoptosis occurs during human and experimental infection with *T. cruzi* (8, 24). Some studies showed evidences that parasites have adapted to their hosts modulating or even taking advantage of cell death in order to facilitate their own survival in a hostile environment and promoting disease. In this context, elucidation of apoptotic cell-mediated signaling mechanisms would help to discover new effective therapies and vaccines.

The modulation of host immune response is an important approach in the efficacy of treatment against *T. cruzi* in the
experimental acute models of Chagas disease. The quality of response could be an important factor, not only in T cell disease progression but also in chemotherapy responsiveness. Apoptosis modulation has a beneficial therapeutic effect in various cardiovascular diseases, as well as infectious diseases (65). There appears to be an association between apoptosis and heart failure, as well as in disease severity in Chagas patients, such that pharmacological use of apoptosis inhibitors could be an attractive choice for adjunctive therapy in the chronic treatment phase; this restores an efficient T cell immune response to parasite infection, thus diminishing the pathological signals of disease.

REFERENCES

1. Costa J, Peterson AT. Ecological niche modeling as a tool for understanding distributions and interactions of vectors, hosts, and eutrophic agents of Chagas disease. Adv Exp Med Biol (2012) 710:59–70. doi:10.1007/978-1-4419-5638-5_7

2. Goldenberg S, Avila AR. Aspects of Trypanosoma cruzi stage differentiation. Adv Parasitol (2011) 75:285–305. doi:10.1016/B978-0-12-385863-4.00013-7

3. Rubin-de-Celis SS, Uemura H, Yoshida N, Senkman S. Expression of trypanotagotide trans-sialidase in metacyclic forms of Trypanosoma cruzi increases parasite escape from its parasitophorous vacuole. Cell Microbiol (2006) 8:1888–98. doi:10.1111/j.1462-5822.2006.00755.x

4. Cardoso MS, Reis-Cunha JL, Bartholomeu DC. Evasion of the immune response by Trypanosoma cruzi during acute infection. Front Immunol (2016) 6:659. doi:10.3389/fimmu.2015.00659

5. Akbar AN, Henson MA. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol (2011) 11:289–95. doi:10.1038/nri2959

6. Gigley JP, Bhdrad R, Moreto MM, Khan IA. T cell exhaustion in protozoan disease. Trends Parasitol (2012) 28:377–84. doi:10.1016/j.pt.2012.07.001

7. Albareda MC, De Rissio AM, Tomas G, Serjan A, Alvarez MG, Viotti R, et al. Functional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults. PLoS Negl Trop Dis (2013) 7:e2575. doi:10.1371/journal.pntd.0002575

8. Freire-de-Lima CG, Nascimento DO, Soares MB, Bozza PT, Castro-Faria-Neto HC, de Mello FG, et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature (2000) 403:199–203. doi:10.1038/3503208

9. Lopes MF, Freire-de-Lima CG, DosReis GA. The macrophase haunted by cell ghosts: a pathogen grows. Immunol Today (2000) 21:489–94. doi:10.1016/S0167-5699(00)01713-8

10. DosReis GA, Freire-de-Lima CG, Nunes MP, Lopes MF. The importance of aberrant T-cell responses in Chagas disease. Trends Parasitol (2005) 21:237–43. doi:10.1016/j.pt.2005.03.008

11. D’Avila H, Freire-de-Lima CG, Roque NR, Teixeira L, Barja-Fidalgo C, Silva AR, et al. Host cell lipid bodies triggered by Trypanosoma cruzi infection and enhanced by the uptake of apoptotic cells are associated with protaglandin E(2) generation and increased parasite growth. J Infect Dis (2011) 204:951–61. doi:10.1093/infdis/jir382

12. Luna-Gomes T, Filardy AA, Rocha JD, Decote-Ricardo D, LaRocque-de-Freitas IF, Morrot A, et al. Neutrophil increase or reduce parasite burden in Trypanosoma cruzi-infected macrophages, depending on host strain: role of neutrophil elastase. PLoS One (2014) 9:e90582. doi:10.1371/journal.pone.0090582

13. DosReis GA. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res (2011) 44:84–90. doi:10.1590/S0100-87992011000700005

14. Cohen TS, Jones-Nelson O, Hotz M, Cheng L, Miller LS, Sузич J, et al. S. aureus blocks effecortocysis of neutrophils by macrophages through the activity of its virulence factor alpha toxin. Sci Rep (2016) 6:35466. doi:10.1038/srep35466

15. Green DR, Ogum J, Martinez J. The clearing of dying cells: table for two. Cell Death Differ (2016) 23:915–26. doi:10.1038/cdd.2015.172

16. Greenlee-Wacker MC. Clearance of apoptotic neutrophils and resolution of inflammation. Immunol Rev (2016) 273:357–70. doi:10.1111/imr.12453

AUTHOR CONTRIBUTIONS

DD-R, MN, AM, and CGF-de-L wrote the paper. All authors read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

This work was supported by grants from Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de Desenvolvimento Cientifico e Tecnológico do Brasil (CNPq).
mechanism adopted by *Trypanosoma cruzi* to ensure its persistence in the infected host. *Front Microbiol* (2016) 7:698. doi:10.3389/fmicb.2016.00698

33. Previti JO, Jones C, Xavier MT, Wair T, Traversos LR, Parodi AJ, et al. Structural characterization of the major glycosylphosphatidylinositol membrane-anchored glycoprotein from epimastigote forms of *Trypanosoma cruzi* Y-strain. *J Biol Chem* (2005) 270:7241–50. doi:10.1074/jbc.270.13.7241

34. Freire-de-Lima CG, Nunes MP, Corte-Real S, Soares MP, Previti JO, Mendonca-Previti L, et al. Proapoptotic activity of a *Trypanosoma cruzi* ceramide-containing glycolipid turned on in host macrophages by IFN-γ. *J Immunol* (1998) 161:4909–16.

35. Wylie AH. Apoptosis and carcinogenesis. *Eur J Cell Biol* (1997) 73:189–97.

36. Kuzmenko DI, Klimentyeva TK. Role of ceramide in apoptosis and development of insulin resistance. *Biochemistry (Moscow)* (2006) 81:913–27. doi:10.1134/ S0006297916090017

37. Huang JR, Tsai YC, Chang YL, Wu JC, Hung JT, Lin KH, et al. alpha-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egt2/3. *J Immunol* (2014) 192:1972–81. doi:10.4049/jimmunol.1302623

38. Schaumburg F, Hippe D, Vutova P, Luder CG. Pro- and anti-apoptotic activities of protzoan parasites. *Parasitology* (2006) 132 Suppl:S69–85. doi:10.1017/S003118200600874

39. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. *Cell Death Differ* (2008) 15:243–50. doi:10.1038/sj.cdd.4402184

40. Hermetet F, Jacquin E, Launay S, Gaiffé E, Couturier M, Hirchaud F, et al. Oxidants selectively reverse TGF-beta suppression of proinflammatory cytokine production in response to apoptotic cells. *Cell Death Dis* (2016) 7:e2173. doi:10.1038/journal.pntd.0002173

41. Elliott MR, Koster KM, Murphy PS. Efferocytosis signaling in the regulation of macrophage inflammatory responses. *J Immunol* (2017) 198:1387–94. doi:10.4049/jimmunol.1601520

42. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. *Nature* (1997) 390:350–1. doi:10.1038/37022

43. Fadok VA, Bratton DL, Jakubzick CV, Henson PM. Myeloid cell turnover and clearance. *Microb Spectr* (2016) 4. doi:10.1128/microbiolspec.MCHD-0005-2015

44. Elliott MR, Koster KM, Murphy PS. Efferocytosis signaling in the regulation of macrophage inflammatory responses. *J Immunol* (2017) 198:1387–94. doi:10.4049/jimmunol.1601520

45. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, et al. Apoptotic cell clearance following acute and chronic lung inflammation. *Semin Immunopathol* (2016) 38:409–23. doi:10.1007/s00281-016-0555-3

46. Grabiec AM, Russell T. The role of airway macrophages in apoptotic cell clearance and exacerbation of chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* (2011) 45:154–60. doi:10.1165/rcmb.2010-0075OC

47. Xiao YQ, Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, et al. Apoptosis and clearance of apoptotic cells in vitro. *J Immunol* (2005) 174:1878–94. doi:10.4049/jimmunol.1601520

48. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. *Nature* (1997) 390:350–1. doi:10.1038/37022

49. Elliott MR, Koster KM, Murphy PS. Efferocytosis signaling in the regulation of macrophage inflammatory responses. *J Immunol* (2017) 198:1387–94. doi:10.4049/jimmunol.1601520

50. Hanayama R, Tanaka M, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. *Nature* (2002) 417:182–7. doi:10.1038/417182a

51. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. *J Clin Invest* (1992) 90:1513–22. doi:10.1172/JCI116019

52. Grabez AM, Russell T. The role of airway macrophages in apoptotic cell clearance and exacerbation of chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* (2011) 45:154–60. doi:10.1165/rcmb.2010-0075OC

53. Penberthy KK, Ravichandran KS. Apoptotic cell recognition receptors and scavenger receptors. *Immunol Rev* (2016) 269:44–59. doi:10.1111/imr.12376

54. Roszer T. Transcriptional control of apoptotic cell clearance by macrophage nuclear receptors. *Aptosis* (2017) 22:284–94. doi:10.1007/s10495-016-1310-x

55. Ariyanayagam MR, Oza SL, Mehlert A, Fairlamb AH. Bis(glutathionyl)serine: a novel trypanothione mimic and other novel trypanothione analogues in *Trypanosoma cruzi*. *Exp Parasitol* (2016) 278:27612–9. doi:10.1016/j.exppara.2016.01.008

56. Molina-Berrios A, Campos-Estrada C, Henriquez N, Faundez M, Torres G, Castillo C, et al. Protective role of acetylsalicylic acid in experimental *Trypanosoma cruzi* infection: evidence of a 15-epi-lipoxin A4-mediated effect. *PLoS Negl Trop Dis* (2013) 7:e2177. doi:10.1371/journal.pntd.0002173

57. Moraes KC, Diniz LF, Bahia MT. Role of cyclooxygenase-2 in *Trypanosoma cruzi* survival in the early stages of parasite-host cell interaction. *Mem Inst Oswaldo Cruz* (2015) 110:181–91. doi:10.1590/0074-02760140311

58. Cossentini LA, Da Silva RV, Yamada-Ogatta SF, Yamauchi LM, De Almeida Araujo EJ, Pinge-Filho P. Aspirin treatment exacerbates oral infections by *Trypanosoma cruzi*. *Exp Parasitol* (2016) 164:64–70. doi:10.1016/j.exppara.2016.01.008

59. Michelin MA, Silva JS, Cunha FQ. Inducible cyclooxygenase released by human primary fibroblasts. *Biol Cell* (2010) 102:285–90. doi:10.1146/annurev.cellbio.042909.101024

60. Michelin MA, Silva JS, Cunha FQ, Inducible cyclooxygenase released by human primary fibroblasts. *Biol Cell* (2010) 102:285–90. doi:10.1146/annurev.cellbio.042909.101024

61. Michelin MA, Silva JS, Cunha FQ, Inducible cyclooxygenase released by human primary fibroblasts. *Biol Cell* (2010) 102:285–90. doi:10.1146/annurev.cellbio.042909.101024

Conflict of Interest Statement: The authors of the review declare that the study was conducted in the absence of financial or commercial relationships that could be construed as a potential conflict of interest. Copyright © 2017 Decote-Ricardo, Nunes, Morrot and Freire-de-Lima. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.